Cellosaurus WM1799 (CVCL_A341)

Cell line name WM1799
Synonyms WM-1799; WM 1799
Accession CVCL_A341
Resource Identification Initiative To cite this cell line use: WM1799 (RRID:CVCL_A341)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: Wistar Institute melanoma cell line collection.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: Amelogenin: X->X,Y.
Sequence variations Heterozygous for BRAF p.Val600Glu (c.1799T>A) (Wistar).
Hemizygous for PTEN deletion (Wistar).
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): Wistar

Markers:
AmelogeninX,Y
CSF1PO11
D13S31711,12
D16S53911
D18S5113,16
D19S43316,16.2
D21S1130
D2S133818
D3S135814,15
D5S81811
D7S8209
D8S117912,14
FGA19,24
TH019.3
TPOX8
vWA14,17
Web pages https://www.wistar.org/our-scientists/meenhard-herlyn
http://www.rockland-inc.com/Product.aspx?id=50734
Publications

PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004)

PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x
Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., Dummer R.
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 19:290-302(2006)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

Cross-references
Cell line databases/resources CCLE; WM1799_SKIN
Gene expression databases GEO; GSM109032
GEO; GSM186477
GEO; GSM186478
GEO; GSM887736
GEO; GSM888831
Other Wikidata; Q54994197
Polymorphism and mutation databases Cosmic; 888851
Cosmic; 1155560
Cosmic; 1303067